
Sign up to save your podcasts
Or


What is the optimal therapeutic strategy in non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in patients not pretreated with P2Y12 adenosine diphosphate receptor antagonists, and why reduce the time to invasive strategy in NSTE-ACS? In this interview, John Gorcsan, Laurent Bonello, and Arjun Majithia discuss the EARLY trial (Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment).
By American College of Cardiology3.8
5454 ratings
What is the optimal therapeutic strategy in non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in patients not pretreated with P2Y12 adenosine diphosphate receptor antagonists, and why reduce the time to invasive strategy in NSTE-ACS? In this interview, John Gorcsan, Laurent Bonello, and Arjun Majithia discuss the EARLY trial (Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment).

137 Listeners

320 Listeners

498 Listeners

169 Listeners

885 Listeners

289 Listeners

140 Listeners

1,156 Listeners

41 Listeners

195 Listeners

90 Listeners

364 Listeners

431 Listeners

371 Listeners

32 Listeners